Literature DB >> 28094434

The effect of remifentanil on propofol requirements to achieve loss of response to command vs. loss of response to pain.

H B Scott1, S W Choi1, G T C Wong1, M G Irwin1.   

Abstract

When providing total intravenous anaesthesia, careful selection of end-points is required in titrating dose to effect during induction. Although propofol and remifentanil have predominantly different pharmacodynamic effects, they are seen to interact in achieving loss of consciousness and analgesia. To highlight these differences, we performed a double-blind, randomised controlled trial, comparing one group of patients receiving propofol alone (n = 42) with another group receiving remifentanil plus propofol (n = 46) as a target-controlled infusion of remifentanil (Minto; 3 ng.ml-1 ). Propofol was also titrated using a target-controlled infusion (Marsh effect model) to produce loss of response to tactile and vocal stimuli, and subsequently to loss of response to pain. The effect-site concentration of propofol at which 50% of patients lost tactile/verbal response was 2.9 μg.ml-1 in the propofol only group and 2.4 μg.ml-1 in the remifentanil with propofol group. In contrast, loss of pain response occurred at 4.4 μg.ml-1 in the propofol group, and 2.7 μg.ml-1 in the remifentanil with propofol group, with correspondingly lower bispectral index values. Judicious use of analgesia in total intravenous anaesthesia can have a propofol-sparing effect and potentially minimise the suppression of brain electrical activity. .
© 2017 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Keywords:  bispectral index (BIS); pain; propofol; remifentanil; total intravenous anaesthesia (TIVA)

Mesh:

Substances:

Year:  2017        PMID: 28094434     DOI: 10.1111/anae.13781

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  7 in total

1.  Remifentanil does not inhibit sugammadex reversal after rocuronium-induced neuromuscular block in the isolated hemidiaphragm of the rat: an ex vivo study.

Authors:  Jae Moon Choi; Ha-Jung Kim; Hey Ran Choi; Yong Beom Kim; Hyeun Joon Bae; Hong Seuk Yang
Journal:  J Anesth       Date:  2019-09-18       Impact factor: 2.078

Review 2.  Different perspectives for monitoring nociception during general anesthesia.

Authors:  Pablo Martinez-Vazquez; Erik Weber Jensen
Journal:  Korean J Anesthesiol       Date:  2022-02-17

3.  Changes of Entropy Index and Cerebral Oxygen Metabolism in the Maintenance of Remifentanil Anesthesia and Their Predictive Value for Postoperative Hyperalgesia.

Authors:  Tianhao Zhang; Fang Ma
Journal:  Comput Math Methods Med       Date:  2022-03-11       Impact factor: 2.238

4.  Comparison of desflurane and propofol in the speed and the quality of emergence from anesthesia in patients undergoing lung cancer surgery-a prospective, randomized study.

Authors:  Izumi Kawagoe; Masakazu Hayashida; Daizoh Satoh; Chieko Mitaka
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

5.  Comparison of dexmedetomidine and remifentanil infusion in geriatric patients undergoing outpatient cataract surgery: a prospective, randomized, and blinded study.

Authors:  Cem Kaya; Nalan Ornek Celebi; Sehend Debbag; Ozgur Canbay; Ozkan Onal
Journal:  Med Gas Res       Date:  2022 Oct-Dec

6.  Effect of dexamethasone on intraoperative remifentanil dose in total knee arthroplasty surgery under general anaesthesia.

Authors:  Maria Gantzel; Kasper Smidt Gasbjerg; Daniel Hägi-Pedersen; Christian Sylvest Meyhoff; Markus Harboe Olsen; Ole Mathiesen; Janus Christian Jakobsen; Troels Haxholdt Lunn
Journal:  Acta Anaesthesiol Scand       Date:  2022-08-04       Impact factor: 2.274

7.  Monosialoganglioside 1 may alleviate neurotoxicity induced by propofol combined with remifentanil in neural stem cells.

Authors:  Jiang Lu; Xue-Qin Yao; Xin Luo; Yu Wang; Sookja Kim Chung; He-Xin Tang; Chi Wai Cheung; Xian-Yu Wang; Chen Meng; Qing Li
Journal:  Neural Regen Res       Date:  2017-06       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.